论文部分内容阅读
目的观察孟鲁司特联合卡介菌多糖核酸治疗婴幼儿哮喘的疗效。方法90例非急性发作期哮喘患儿随机分为3组;Ⅰ组给予孟鲁司特与卡介菌多糖核酸治疗,Ⅱ组给予孟鲁司特治疗,对照组给予酮替酚治疗。遇哮喘急性发作时均给予糖皮质激素、β2受体激动剂及必要的抗感染等强化治疗。结果治疗12周后,Ⅰ组、Ⅱ组多项哮喘控制参数明显改善,与对照组比较有显著性差异(P<0.01),且Ⅰ组明显优于Ⅱ组。结论孟鲁司特和卡介菌多糖核酸联合治疗婴幼儿哮喘,临床控制率较高,患者依从性好。
Objective To observe the efficacy of montelukast combined with BCG polysaccharide nucleic acid in the treatment of infantile asthma. Methods Ninety non-acute exacerbation asthmatic children were randomly divided into three groups: group Ⅰ montelukast and BCG polysaccharide nucleic acid therapy, group Ⅱ montelukast and group control ketotifen. In case of acute exacerbation of asthma are given glucocorticoid, β2 receptor agonist and the necessary anti-infection and other intensive treatment. Results After 12 weeks of treatment, the number of asthma control parameters in group Ⅰ and group Ⅱ improved significantly compared with that in control group (P <0.01), and group Ⅰ was significantly better than group Ⅱ. Conclusion Montelukast and BCG polysaccharide nucleic acid combined treatment of infant asthma, clinical control rate is high, patients with good compliance.